Get the Stockscreener App
2.47
2.76%
-0.07
Q 32 Bio Inc stock is traded at $2.47, with a volume of 162.12K.
It is down -2.76% in the last 24 hours and down -29.83% over the past month.
Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to effectively and safely restore healthy immune balance in patients with autoimmune & inflammatory diseases driven by pathological immune dysfunction. Q32 is advancing antibody-based therapeutic candidates designed to target two central pathways of adaptive & innate immunity. The adaptive immune system is largely composed of T- & B-cell mediated cellular & antibody responses, while the innate immune system is the body's first line of defense employing leukocytes that are responsible for clearing pathogens and cellular debris and modulating T- & B-cell function. ADX-097, the lead product candidate from Q32's complement inhibitor platform, is a humanized anti-C3d monoclonal antibody fusion protein.
See More
Previous Close:
$2.54
Open:
$2.53
24h Volume:
162.12K
Relative Volume:
0.42
Market Cap:
$30.09M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-5.36%
1M Performance:
-29.83%
6M Performance:
-93.75%
1Y Performance:
+0.00%
1-Day Range:
$2.43
$2.61
1-Week Range:
$2.35
$2.71
52-Week Range:
$2.35
$53.79
Q 32 Bio Inc Stock (QTTB) Company Profile
Name
Q 32 Bio Inc
Sector
Industry
Phone
781-999-0232
Address
830 WINTER STREET, WALTHAM
Compare QTTB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
QTTB
Q 32 Bio Inc
|
2.47 | 30.09M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
480.35 | 123.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
723.47 | 79.09B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
624.94 | 37.97B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.20 | 31.74B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
259.70 | 27.71B | 3.32B | -860.46M | -1.04B | -8.32 |
Q 32 Bio Inc Stock (QTTB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-11-25 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Feb-11-25 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-11-24 | Downgrade | Guggenheim | Buy → Neutral |
| Dec-11-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Dec-11-24 | Downgrade | Raymond James | Strong Buy → Outperform |
| Dec-11-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Dec-06-24 | Initiated | BMO Capital Markets | Outperform |
| Oct-24-24 | Initiated | Raymond James | Strong Buy |
| Sep-11-24 | Initiated | Wells Fargo | Overweight |
| Jun-17-24 | Initiated | Guggenheim | Buy |
| May-21-24 | Initiated | Leerink Partners | Outperform |
| Apr-11-24 | Initiated | Oppenheimer | Outperform |
| Apr-02-24 | Initiated | Piper Sandler | Overweight |
| Jul-28-23 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Feb-22-22 | Reiterated | BTIG Research | Neutral |
| Feb-22-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Feb-22-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Mar-02-21 | Initiated | Stifel | Hold |
| Dec-14-20 | Resumed | H.C. Wainwright | Buy |
| Aug-11-20 | Reiterated | H.C. Wainwright | Buy |
| Jun-25-20 | Resumed | BofA/Merrill | Buy |
| May-13-20 | Initiated | RBC Capital Mkts | Outperform |
| Mar-16-20 | Upgrade | Oppenheimer | Perform → Outperform |
| Feb-24-20 | Initiated | Chardan Capital Markets | Buy |
| Nov-01-19 | Initiated | Oppenheimer | Perform |
| Sep-10-19 | Initiated | Robert W. Baird | Outperform |
| Apr-12-19 | Initiated | Evercore ISI | Outperform |
View All
Q 32 Bio Inc Stock (QTTB) Latest News
Fierce Biotech Layoff Tracker 2025: Moderna lays off 50 employees; Spotlight winds down - Fierce Biotech
Savant Capital LLC Makes New $53,000 Investment in Q32 Bio Inc. (NASDAQ:QTTB) - Defense World
Layoff Tracker: Spotlight Goes Dark After Disappointing Preclinical Data for CRISPR Platform - BioSpace
QTTB stock touches 52-week low at $2.44 amid market challenges - Investing.com
Piper Sandler cuts Q32 Bio stock rating to neutral, slashes target - MSN
What is Leerink Partnrs’ Forecast for Q32 Bio Q1 Earnings? - Defense World
Petri Dish: a new AbbVie deal, layoffs, and CFO departures - The Business Journals
Bleakley Financial Group LLC Invests $149,000 in Q32 Bio Inc. (NASDAQ:QTTB) - Defense World
Q32 Bio refocuses on alopecia treatment, ends renal trial - MSN
BMO cuts Q32 Bio stock rating, slashes price target to $3 - MSN
BMO Capital Downgrades Q32 Bio (LSE:0T6G) - Nasdaq
Q32 Bio (NASDAQ:QTTB) Lowered to “Market Perform” Rating by BMO Capital Markets - Defense World
Finance Watch: Third Harmonic, Q32 Bio Cut Jobs To Focus On Lead Assets - News & Insights
Q32 Bio halts trials amid job cuts and pivots to alopecia treatment - MSN
Q32 cut to neutral by Piper on ADX-097 discontinuation - MSN
Q32 Bio refocuses on alopecia treatment, ends renal trial By Investing.com - Investing.com Australia
BMO cuts Q32 Bio stock rating, slashes price target to $3 By Investing.com - Investing.com South Africa
Piper Sandler cuts Q32 Bio stock rating to neutral, slashes target By Investing.com - Investing.com South Africa
Piper Sandler Downgrades Q32 Bio (LSE:0T6G) - Nasdaq
This Columbus McKinnon Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday - Benzinga
Q32 Bio lays off staff, focuses on alopecia program - The Pharma Letter
Q32 Bio sticks with bempikibart but loses staff and phase 2 complement inhibitor - Fierce Biotech
Brokerages Set Q32 Bio Inc. (NASDAQ:QTTB) Price Target at $29.86 - Defense World
FY2025 EPS Estimates for Q32 Bio Cut by Leerink Partnrs - Defense World
Q32 Bio Inc Restructuring Plan Includes Reduction In Force, Which Co Expects To Substantially Complete By End Of Q2 Of 2025 - Marketscreener.com
Q32 Bio Inc To Discontinue Renal Basket Trial For Adx-097 To Conserve Resources - Marketscreener.com
Q32 Bio Restructures to Focus on Bempikibart Development - TipRanks
Q32 Bio Announces Strategic Restructuring to Focus on Advancement of Bempikibart in Patients with Alopecia Areata - PR Newswire
Q32 Bio to Participate in Oppenheimer's 35th Annual Healthcare Life Sciences Conference - The Eastern Progress Online
QTTB stock touches 52-week low at $2.95 amid market challenges - MSN
Barclays PLC Acquires 5,353 Shares of Q32 Bio Inc. (NASDAQ:QTTB) - Defense World
Q32 Bio Inc. (NASDAQ:QTTB) Receives $29.86 Consensus Target Price from Brokerages - Defense World
Q32 Bio Advances Clinical Trials for Growth Opportunities - TipRanks
Pre-market Movers: ONCO, EYEN, SGMO, VSTM... - RTTNews
Q32 Bio Inc (QTTB) Could Be Worth Considering For The Next Few Weeks - Stocks Register
Arq Inc (ARQ) Analyst Thoughts: How High Can It Go? - Stocks Register
Analysts Update Their Estimates For Brunswick Corp - Stocks Register
At $1.81 Price, XCHG Ltd ADR (XCH) Is Sitting And Waiting - Stocks Register
Analysts Update Their Estimates For EPR Properties - Stocks Register
Protagenic Therapeutics Inc’s (PTIX) -12.44% Retreat Justifies A Second Look - Stocks Register
LegalZoom.com Inc (LZ) Volatility Hits 3.83% – Here Is What You Should Do - Stocks Register
At $18.67 Price, Osisko Gold Royalties Ltd (OR) Is Sitting And Waiting - Stocks Register
First Foundation Inc (FFWM): A New Perspective - Stocks Register
Analyst Updating Price Targets And Ratings For Springview Holdings Ltd (SPHL) - Stocks Register
Q 32 Bio Inc Stock (QTTB) Financials Data
There is no financial data for Q 32 Bio Inc (QTTB). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
0.53%
0.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):